Multipollutant, longitudinal analysis of the association between urinary tungsten and incident diabetes in a rural population

Emily Riseberg*†, Katherine A. James‡, Mark Woodin§, Rachel Melamed∥, Tanya Alderete¶, Laura Corlin**

**Background:** Cross-sectional studies suggest tungsten (W) exposure may be associated with diabetes. We assessed longitudinal associations between urinary W and fasting glucose, 2-hour glucose, insulin resistance (HOMA-IR), β-cell function (HOMA-β), and incident type 2 diabetes.

**Methods:** We used data from 1,609 Hispanic and non-Hispanic White adults with 20 to 74 years of age residing in rural Colorado and participating in the San Luis Valley Diabetes Study. Urinary metal exposure values were measured at baseline and natural log-transformed. We assessed longitudinal associations between urinary W and continuous outcome measures using linear-mixed effect models and associations with incident diabetes using Fine and Gray competing risks regression models (competing event = all-cause mortality). The main adjustment set of covariates included: age, sex, ethnicity, education, smoking status, hypertension, body mass index, caloric intake, alcohol intake, and urinary creatinine levels. Secondary models were further adjusted for arsenic, cadmium, and lead exposures. We assessed whether sex or ethnicity were effect modifiers.

**Results:** At baseline, the median W concentration was 0.22 μg/L (interquartile range = 0.20, 0.59). In the main cross-sectional analyses, lnW levels were significantly associated with 3% higher lnHOMA-IR (95% CI = 1 to 5). In the main longitudinal models, lnW was significantly associated with 1% higher natural log-transformed fasting glucose (95% CI = <1 to 1), 3% higher natural log-transformed HOMA-IR (95% CI = 2 to 5), and 28% higher incident diabetes (subdistribution hazard ratio=1.28, 95% CI = 1.09 to 1.50). Results significantly associated with 1% higher natural log-transformed fasting glucose (95% CI = <1 to 1), 3% higher natural log-transformed HOMA-IR (95% CI = 2 to 5), and 28% higher incident diabetes (subdistribution hazard ratio=1.28, 95% CI = 1.09 to 1.50). Results remained significant when further adjusting for other metals. We observed evidence for effect modification by sex and ethnicity.

**Conclusion:** Urinary W was longitudinally associated with adverse metabolic health indicators.

**Introduction**

In the United States, 34.1 million adults (13% of the adult population) have diabetes mellitus, and approximately 90 to 95% of cases are type 2 diabetes (hereafter, diabetes). Although the prevalence is high among most subpopulations, diabetes disproportionately affects individuals residing in rural areas. Diabetes is a complex disorder that develops as a result of both genetic and environmental factors. For example, toxicological and epidemiologic studies suggest that exposure to certain metals (e.g., arsenic, cadmium, and lead) may be associated with diabetes and impaired fasting glucose levels through mechanisms including oxidative stress and inflammation, impaired glucose metabolism, and impaired insulin secretion and storage.

Tungsten (W) is a transitional metal found naturally in soil, water, food, air, and particulate matter. The use of W in industrial settings has been increasing due to its high melting point, flexibility, and strength. W is also frequently found in household items and medical supplies. Currently, there are no federal guidelines on the levels of W in drinking water, but W has been listed as an emerging metal of concern by the Environmental Protection Agency and the National Toxicology Program. Individuals who work with W or who live in areas with high levels of W in the water may have elevated urinary W compared with the general population. W has been associated with increased incidence of lung cancer, high blood pressure, stroke, and chronic kidney disease. Cross-sectional studies conducted in the United States and China suggest that urinary W is also positively associated with fasting glucose and diabetes prevalence. However, no cross-sectional studies have examined associations between W and certain other markers of
diabetes (e.g., β-cell function), and no longitudinal studies of which we are aware have examined the association between W and any continuous biomarker of diabetes.

Additionally, although W may potentiate adverse health effects of exposure to metals such as cobalt and nickel, no studies have examined how relationships between W and diabetes may be affected by coexposure to other elements. One study among US women found that overall exposure to metal mixtures was associated with diabetes incidence, but W was not included in the mixture analyses due to a low percentage of participants with detectable measurements. Finally, despite known sex differences in the risk factors for and pathophysiology of diabetes, and despite structural racism that results in differential exposure to diabetes risk factors by ethnicity, no previous studies examined whether sex or ethnicity modify associations between W and diabetes.

We sought to address these gaps in the literature using data from the prospective San Luis Valley Diabetes Study (SLVDS). This study population is of particular concern since the W levels in the water sources are elevated due to depleting water supply. Specifically, our a priori primary objective was to assess whether urinary W levels were longitudinally associated with fasting glucose levels, 2-hour glucose levels, insulin resistance, β-cell function, and diabetes incidence. Our a priori secondary objectives were to assess whether these associations were robust when adjusting for coexposure to other metals and to assess whether sex or ethnicity modified the associations.

Methods

Study population

The San Luis Valley is a rural region of Colorado covering over 8,000 square miles in six counties (including Alamosa and Conejos counties) with a total population of about 46,000 residents. Approximately 49% of the people in the region identify as Hispanic. Participant recruitment and data collection methods for the SLVDS have been described previously. Briefly, the SLVDS was designed to investigate risk factors for diabetes and other chronic diseases among Hispanic and non-Hispanic White adults. The primary identification stage of recruitment differed for diabetics and nondiabetics, and recruitment in each category included two phases with the same recruitment protocols (phase 1: 1984–1985; phase 2: 1986–1987). Participants were considered to have hypertension if their average systolic blood pressure was ≥140 mmHg, their average diastolic blood pressure ≥90 mmHg, or if they currently used blood pressure-lowering medication. Height and weight measured at the examination were used to calculate body mass index (BMI; kg/m²; obesity defined as BMI ≥ 30 kg/m²). A food frequency questionnaire was used to calculate the participants’ total caloric intake per day and alcohol intake per week.

Urine samples (approximately 120ml) were collected in trace metal-free tubes at baseline examination cycles between 1984 and 1988. Samples were stored in a freezer at −80°C until they were analyzed in 2008 and 2015 at two laboratories as part of separate studies. In 2008 (n = 529) and 2015 (n = 304), the Colorado Department of Public Health and Environment chemistry laboratory analyzed a full metals panel (including W, antimony, arsenic, barium, cadmium, cesium, chromium, cobalt, copper, lead, manganese, molybdenum, plutonium, selenium, thallium, uranium, and zinc) on 1,033 urine samples. In 2015, Columbia University Metals Laboratory analyzed a full metals panel for an additional 576 samples. Both laboratories met the standards of the Clinical Laboratory Improvement Amendment. They used an inductively coupled argon plasma instrument with a mass spectrometer to detect metal concentrations (detection limit for each metal = 1 part in 10¹²) and a colorimetric assay by the Jaffe reaction to assess urinary creatinine levels. For urine samples with metal concentrations below the level of detection, concentrations were imputed using the square root of the limit of detection divided by two.

Outcome measures (fasting glucose, 2-hour glucose, insulin resistance, β-cell function, and diabetes status) were assessed at each examination cycle. Participants fasted for at least eight hours before the examination. Blood was drawn once before consuming glucose through a flavored drink and again at 1 and 2 hours after consumption to collect data on glucose and insulin levels. Participants with diabetes using insulin did not inject the insulin until after the first blood sample was collected, and participants taking oral hypoglycemic medication took the medication before the examination. Glucose was measured using the glucose oxidase method with venous plasma, and insulin was measured with a double antibody radioimmunoassay. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated as the product of fasting insulin (µU/mL; to convert to pmol/L, multiply by 0.144) and fasting glucose (mg/dL; to convert to mmol/L, multiply by 0.056) divided by 405. Homeostatic Model Assessment of β-cell function (HOMA-β) was calculated as [20 times fasting insulin (µU/mL)/fasting glucose (mg/dL) minus 63]. Participants were considered to have diabetes if they had been previously diagnosed with diabetes by a health professional at the time of recruitment, if they were currently taking insulin or diabetes medication, or if they would be classified as having diabetes according to the World Health Organization guidelines for the glucose tolerance test (fasting venous plasma glucose ≥140 mg/dL or 2-hour venous plasma glucose ≥200 mg/dL).

At follow-up, diabetes was diagnosed according to the same guidelines used at baseline.

Statistical methods

We first examined univariate distributions of urinary W, outcomes, and covariates in the full analytic sample (n = 1,609;
Figure 1. Analysis sample selection scheme.

Fasting glucose model: Participants with baseline fasting glucose and baseline covariate data (n = 1567)

2-hour glucose model: Participants with baseline 2-hour glucose and baseline covariate data (n = 1485)

HOMA-IR and HOMA-β models:
Participants with baseline fasting glucose, baseline fasting insulin, and baseline covariate data (n = 1401 for HOMA-IR; n = 1399 for HOMA-β)

Diabetes prevalence model: Participants with baseline diabetes status and baseline covariate data (n = 1573)

Fasting glucose model: Participants with fasting glucose and baseline covariate data (n = 1078)

2-hour glucose model: Participants with 2-hour glucose and baseline covariate data (n = 1050)

HOMA-IR and HOMA-β models:
Participants with fasting glucose, fasting insulin and baseline covariate data (n = 1054)

Diabetes incidence model: Participants with diabetes status and baseline covariate data (n = 1056)
diabetes prevalence). We evaluated whether lnW was longitudinally associated with each outcome variable among the participants without diabetes at baseline using linear mixed effect models with a random intercept for each participant (for lnFG, lnFG-2hr, lnHOMA-IR, and lnHOMA-β) and Fine and Gray competing risks regression (for incident diabetes, competing event = all-cause mortality). Although the proportional hazards assumption was not met for the Fine and Gray competing risks regression \((p = 0.001)\), our sample size was large \((n > 1,000)\) and the Kaplan-Meier survival estimates seemed to approximately follow the proportional hazards assumption beyond 10 years (eFigure 3; http://links.lww.com/EE/A156), so we assumed that the modeling method was still appropriate. To assess whether sex or ethnicity modified associations, we ran sex- and ethnicity-stratified models (separately). As a sensitivity analysis to reduce the potential for error in W estimation, we estimated the primary cross-sectional and longitudinal models excluding participants with baseline W concentrations below the limit of detection \((n = 525\) at baseline). Finally, we included a sensitivity analysis of longitudinal models using quartiles of urinary W rather than log-transformed values as the exposure.

All multivariable models were estimated twice—once each with two sets of covariates determined a priori using an evidence-based directed acyclic graph (DAG; eFigure 4; http://links.lww.com/EE/A156). The set of covariates in the main models and the BKM-R model included baseline values of age (included as the unit of time for the mixed effect models), sex (excluded in the models stratified by sex), ethnicity (Hispanic, not Hispanic; excluded in models stratified by ethnicity), education (<12 years, 12 years, >12 years of schooling), smoking status (never, former, current), hypertension, body mass index \((\text{BMI}; \text{kg/m}^2)\), caloric intake \((\text{kcal/day})\), alcohol intake \((\text{g/week})\), and urinary creatinine levels \((\text{g/L})\). The set of covariates included in the further adjusted models also included natural log-transformed baseline values of arsenic \((\text{lnAs})\), cadmium \((\text{lnCd})\), and lead \((\text{lnPb})\).

### Results

Characteristics of the participants at baseline are described in Table 1. At baseline, the median W concentration was 0.22 µg/L (interquartile range \([\text{IQR}]\) = 0.20, 0.59; see eTable 1; http://links.lww.com/EE/A156 for baseline distribution of all urinary metal exposures). In bivariate analyses, having urinary W above the median was significantly associated with being male, non-Hispanic, a current/former smoker, having differing levels of attained education, higher alcohol intake, lower fasting glucose, lower 2-hour glucose, and lower diabetes prevalence (Table 1). Baseline lnW concentrations were statistically significantly correlated with lnAs \((r = 0.51)\) and weakly (but significantly) correlated with lnCd and lnPb levels \((r = 0.16, 0.08,\) respectively; eTable 2; http://links.lww.com/EE/A156).

### Table 1.

Baseline characteristics of the study sample stratified by tungsten \((W)\) concentrations above and below the median

| All n (%) or mean (standard deviation) | W ≤ 0.22 µg/L n (%) or mean (standard deviation) | W > 0.22 µg/L n (%) or mean (standard deviation) | \(P\) value for difference by urinary W group
|--------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|
| Total 1,609 (100)                   | 805 (50.0)                                      | 804 (50.0)                                      | 0.120                                       |
| Age 54.3 (12.2)                     | 54.7 (12.3)                                     | 53.3 (12.1)                                     | <0.001*                                     |
| Sex Men 754 (46.9)                  | 330 (41.0)                                      | 424 (52.7)                                      |                                             |
| Women 855 (53.1)                    | 475 (59.0)                                      | 380 (47.3)                                      |                                             |
| Ethnicity Hispanic 773 (48.0)       | 460 (57.1)                                      | 313 (38.9)                                      | <0.001*                                     |
| Non-Hispanic 836 (52.0)             | 345 (42.9)                                      | 491 (61.1)                                      |                                             |
| Education <12 years 526 (32.8)      | 302 (37.5)                                      | 224 (28.0)                                      | <0.001*                                     |
| 12 years 540 (33.6)                 | 271 (33.7)                                      | 269 (33.6)                                      |                                             |
| >12 years 539 (33.6)                | 232 (28.8)                                      | 307 (38.4)                                      |                                             |
| Smoking status\(^a\) \(\text{Never}\) 721 (44.9)  | 398 (49.4)                                      | 323 (40.3)                                      | 0.001*                                     |
| \(\text{Current}\) 387 (24.1)       | 172 (21.4)                                      | 215 (26.8)                                      |                                             |
| \(\text{Former}\) 499 (31.1)       | 235 (29.2)                                      | 264 (32.9)                                      |                                             |
| Hypertension prevalence 627 (39.0)  | 322 (40.1)                                      | 305 (38.0)                                      | 0.396                                      |
| Body mass index \((\text{kg/m}^2)\) 26.7 (4.81)  | 26.9 (4.90)                                     | 26.5 (4.62)                                     | 0.127                                      |
| Caloric intake \((\text{kcal/day})\) 1,510 (578)  | 1,523 (594)                                     | 1,498 (562)                                     | 0.388                                      |
| Alcohol \((\text{g/week})\) 41.0 (104)  | 31.5 (91.7)                                     | 50.6 (115)                                      | <0.001*                                     |
| Fasting glucose \((\text{mg/dL})\) 120 (56.0)  | 122 (61.0)                                      | 117 (50.3)                                      | 0.039*                                     |
| 2-hour glucose \((\text{mg/dL})\) 154 (101)  | 160 (106)                                       | 148 (94.7)                                      | 0.026*                                     |
| Fasting insulin \((\text{µU/mL})\) 14.6 (10.5)  | 14.4 (8.83)                                     | 14.8 (11.0)                                     | 0.434                                      |
| HOMA-IR 4.19 (4.13)                 | 4.20 (4.21)                                     | 4.18 (4.05)                                     | 0.938                                      |
| HOMA-β 7.65 (8.41)                  | 7.69 (10.3)                                     | 7.61 (8.15)                                     | 0.858                                      |
| Diabetes prevalence\(^c\) 457 (28.4)  | 249 (30.9)                                      | 208 (25.9)                                      | 0.024*                                     |
| Study time to death, diabetes, or censoring \((\text{years})\) 10.4 (5.14)  | 10.3 (4.92)                                     | 10.4 (5.35)                                     | 0.791                                      |

\(^a\)Significant with \(p < 0.05\)

\(^b\)Differences between baseline categorical and continuous covariate measurements were assessed using chi-squared and t-tests, respectively, among those below or at the median W value and above the median W value.

\(^c\)Smoking status of never was defined as <100 cigarettes in lifetime. Smoking status of current was defined as ≥100 cigarettes in lifetime and currently a smoker. Smoking status of ever was defined as ≥100 cigarettes in lifetime and not currently a smoker.

\(^d\)Caloric intake and alcohol intake were measured using a food frequency questionnaire.

\(^e\)Si conversion factors: to convert mg/dL to mmol/L, multiply by 0.056. To convert µU/mL to pmol/L, multiply by 0.144.

\(^f\)Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated as the product of fasting insulin \((\mu U/mL)\) and fasting glucose \((\text{mg/dL})\) divided by 405. Homeostatic Model Assessment of beta cell function (HOMA-β) was calculated as \([20 \times \text{fasting insulin} (\mu U/mL)] / (\text{fasting glucose} (\text{mg/dL}) - 63)\).
Participant characteristics were generally similar among those with and without HOMA-IR or HOMA-β values, although we observed significant differences for ethnicity and BMI (eTable 3; http://links.lww.com/EE/A156).

Of the 1,078 participants without diabetes at baseline, 119 developed diabetes during the study period (mean time at risk = 9.9 years) and 301 participants died before developing diabetes (mean time to death = 14.0 years). The mean follow-up time before a censored event was 10.4 years. Compared with participants who did not develop diabetes, those who developed diabetes were significantly more likely to be older, Hispanic, hypertensive, have differing levels of attained education, and have a higher BMI (eTable 4; http://links.lww.com/EE/A156).

The assumption of linearity seemed reasonable as lnW appeared to be linearly associated with odds of diabetes at baseline except at the highest lnW concentrations (eFigure 5; http://links.lww.com/EE/A156). Tables 2 and 3 show the effect estimates cross-sectionally relating lnW to lnFG, lnFG-2hr, lnHOMA-IR, lnHOMA-β, and diabetes prevalence at baseline. Although lnW was not significantly associated with lnFG, lnFG-2hr, lnHOMA-β, or diabetes prevalence, a doubling of urinary W was significantly associated with 3% higher lnHOMA-IR in the main model overall (95% confidence interval [CI] = 1 to 5 higher), 5% higher among males (95% CI = 2 to 9 higher), and 5% higher among Hispanics (95% CI = 1 to 9 higher; Table 2 and eTable 5; http://links.lww.com/EE/A156). The associations with lnHOMA-IR were not significant in models adjusting for other metals (Table 2 and eTable 5; http://links.lww.com/EE/A156). In a sensitivity analysis excluding participants with urinary W values below the limit of detection and adjusting for exposure to other metals, lnW was significantly associated with 2% decreased lnFG (95% CI = <1 to 3 lower) and 16% lower diabetes prevalence (odds ratio = 0.84; 95% CI = 0.71 to 0.99; eTable 6; http://links.lww.com/EE/A156). In a multipollutant BKMR analysis, antimony, arsenic, and copper appeared to be effect modifiers of the association between lnW and odds of diabetes (eFigure 5; http://links.lww.com/EE/A156).

**Table 2.** Associations between urinary tungsten and continuous diabetes measures

|                     | Cross-sectional associations (β (95% CI)) | Longitudinal associations (β (95% CI)) |
|---------------------|----------------------------------------|--------------------------------------|
| Natural-log transformed fasting glucose |                                      |                                      |
| Main model*          | 0.002 (-0.013, 0.017)                   | 0.008 (0.002, 0.014)*                |
| Further adjusted model* | -0.013 (-0.030, 0.004)               | 0.007 (0.000, 0.013)*                |
| Natural-log transformed 2-hour glucose |                                      |                                      |
| Main model           | 0.005 (-0.018, 0.029)                  | 0.011 (-0.005, 0.028)               |
| Further adjusted model | -0.012 (-0.038, 0.014)            | 0.018 (-0.002, 0.037)               |
| Natural-log transformed HOMA-IR*   |                                      |                                      |
| Main model           | 0.043 (0.011, 0.076)*                  | 0.045 (0.022, 0.069)*               |
| Further adjusted model | 0.027 (-0.010, 0.063)                | 0.041 (0.014, 0.068)*               |
| Natural-log transformed HOMA-β*    |                                      |                                      |
| Main model           | 0.018 (-0.014, 0.050)                 | 0.018 (-0.007, 0.042)               |
| Further adjusted model | 0.028 (-0.008, 0.064)            | 0.020 (-0.009, 0.048)               |

*Significant with p < 0.05.

In longitudinal analyses, lnW was significantly associated with a 1% increased lnFG (main model: 95% CI = <1 to 1 increased; further adjusted model: <1% increased, 95% CI = 0 to 1 increase), 3% increased lnHOMA-IR (main model: 95% CI = 2 to 5 increase; further adjusted model: 3% increase, 95% CI = 1 to 5 increase), and 28% higher incident diabetes (main model: 95% CI = 1.03 to 1.48; Tables 2 and 3). The strength of these associations remained significant after adjusting for coexposure to other metals and the first to examine sex- and ethnicity-stratified associations. We observed that a doubling of urinary lnW was cross-sectionally associated with 3% higher lnHOMA-IR and longitudinally associated with 1% higher lnFG and 3% higher lnHOMA-IR. Similarly, each natural log-unit increase in urinary W was associated with a 28% increased risk of developing diabetes over the follow-up period. These associations were robust when adjusting for the set of covariates suggested by an evidence-based DAG, and when further adjusting for coexposure to arsenic, cadmium, and lead. Although future longitudinal studies are needed to validate our results in other populations, our findings are timely given the diabetes epidemic in the United States, current efforts to develop an oral antidiabetic treatment option that contains tungstate, and ongoing low-level occupational exposure to W. Despite differences in study designs, populations, and exposure levels, our primary findings were in agreement with previous

**Table 3.** Associations between urinary tungsten and diabetes

|                     | Cross-sectional associations with diabetes prevalence OR (95% CI) n = 1,573 | Longitudinal associations with diabetes incidence SHR (95% CI) n = 1,056 |
|---------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------|
| Main model          | 0.98 (0.87, 1.12)                                                          | 1.28 (1.09, 1.50)*                                                 |
| Further adjusted model | 0.87 (0.75, 1.01)                                                          | 1.24 (1.03, 1.48)*                                                 |

*Significant with p < 0.05.

We presented a longitudinal analysis investigating the associations between urinary W, fasting glucose, 2-hour glucose, measures of insulin resistance and β-cell function, and incident diabetes. Our analysis is the first to examine these associations accounting for coexposure to other metals and the first to examine sex- and ethnicity-stratified associations. We observed that a doubling of urinary lnW was cross-sectionally associated with 3% higher lnHOMA-IR and longitudinally associated with 1% higher lnFG and 3% higher lnHOMA-IR. Similarly, each natural log-unit increase in urinary W was associated with a 28% increased risk of developing diabetes over the follow-up period. These associations were robust when adjusting for the set of covariates suggested by an evidence-based DAG, and when further adjusting for coexposure to arsenic, cadmium, and lead.

**Discussion**

We presented a longitudinal analysis investigating the associations between urinary W, fasting glucose, 2-hour glucose, measures of insulin resistance and β-cell function, and incident diabetes. Our analysis is the first to examine these associations accounting for coexposure to other metals and the first to examine sex- and ethnicity-stratified associations. We observed that a doubling of urinary lnW was cross-sectionally associated with 3% higher lnHOMA-IR and longitudinally associated with 1% higher lnFG and 3% higher lnHOMA-IR. Similarly, each natural log-unit increase in urinary W was associated with a 28% increased risk of developing diabetes over the follow-up period. These associations were robust when adjusting for the set of covariates suggested by an evidence-based DAG, and when further adjusting for coexposure to arsenic, cadmium, and lead. Although future longitudinal studies are needed to validate our results in other populations, our findings are timely given the diabetes epidemic in the United States, current efforts to develop an oral antidiabetic treatment option that contains tungstate, and ongoing low-level occupational exposure to W. Despite differences in study designs, populations, and exposure levels, our primary findings were in agreement with previous
cross-sectional studies. Given the differences in study population, the results might be transportable to other populations (our study population was drawn from individuals in one rural location compared with the previous studies that included a sample of adults in one urban region of China and in a nationally representative sample of US adults). Similarly, given the differences in exposure levels, we might expect the associations we observed to extrapolate to somewhat lower exposure levels (our participants were exposed to median urinary W values of 0.22 µg/L compared with median values of 0.12 µg/L and 0.07 µg/L in the two cross-sectional studies). Finally, the associations may not be time period-specific: our study included data collected beginning in 1984 whereas the others collected data beginning in 2011 and 1999, respectively. This difference in time period could also partially explain the difference in urinary W levels, though not the geometric mean in a nationally representative sample of US adults for that time period (95% CI = 0.31 to 0.34 µg/L in our population versus 95% CI = 0.63 to 0.77 µg/L nationally from 1988 to 1994). Another prospective study conducted in US women did not find a significant association between urinary W and incident diabetes; however, this study used above or below the limit of detection as exposed or unexposed, respectively, and only 29% of participants had detectable W levels. Thus, the differences in exposure assessment could explain the discrepancies in results.

Relatively sparse literature exists that would suggest potential mechanisms through which W may affect the development of diabetes. The results from our study indicate that W could influence diabetes risk through insulin resistance rather than β-cell function—though insulin resistance and β-cell dysfunction often interact in the development of diabetes, and it is possible that the measurement methods for HOMA-IR were less accurate (especially for participants on insulin medication). More generally, W can be pro-inflammatory and inflammation can lead to endothelial dysfunction and insulin resistance. This could partially explain the association between W and diabetes incidence as well as between W and HOMA-IR. The association between W and hyperglycemia could also be caused by endothelial dysfunction, as W can affect this process through inhibition of a related antioxidant molybdenum. Additionally, it is possible that other trace metals interact with W (or similarly to W) in its association with diabetes. For example, chromium, another group six transition metal with a high melting point, is involved with the metabolism of glucose and insulin.

Furthermore, there could be sex-differences underlying the mechanisms relating urinary W to diabetes. For example, one study observed that the effect of W on bone homeostasis in mice was sex-dependent. Similarly, sex-related hormonal differences seemed to affect the absorption rate of other metals in humans. Additionally, the mechanisms through which individuals develop diabetes vary by sex and this could partially explain sex differences in our results. For example, consistent with our observation that associations with HOMA-IR were stronger in men than women, males are more likely to have insulin resistance, whereas females are more likely to have impaired glucose tolerance.

Our study had several strengths. These strengths include the longitudinal nature of the analysis, the inclusion of multiple diabetes markers indicative of different possible roles of W in the pathophysiology of diabetes, the ability to adjust for covariates determined through an evidence-based DAG, the ability to adjust for coexposure to toxic metals, and the assessment of sex- and ethnicity-related effect modification. Other strengths include the use of urinary metal measurements (a common method to estimate chronic exposure to most heavy metals), large sample size, low attrition rate, and exposure contrast in our sample. Furthermore, any measurement error in urinary W would likely be nondifferential (biasing the results toward the null) since measurement error would not depend on diabetes status.

Our study also had several limitations. For example, we used the oral glucose tolerance test rather than robust measures of whole body insulin resistance and β-cell function (e.g., the hyperglycemic or hyperinsulinemic-euglycemic clamp, or the frequently sampled intravenous glucose tolerance test) to assess HOMA-IR, HOMA-β, and plasma glucose levels. Nonetheless, we observed significant associations with other markers of diabetes in addition to insulin resistance calculated through the HOMA-IR model. We also used the WHO criteria from 1985 to classify participants with diabetes, as this was the criteria used at the time of data collection. This definition required a fasting glucose level of at least 140 mg/dL to diagnose diabetes, whereas current guidelines recommend a cutoff of 126 mg/dL. We used the guidelines at the time of data collection to follow the clinical decision-making process at the time. Nonetheless, we recognize that there could have been undiagnosed cases of diabetes. It is possible that our outcome misclassification was differential, in part due to missing data patterns whereby participants who identified as non-Hispanic and who had a higher BMI were more likely to be missing fasting glucose and fasting

### Table 4

|                        | Males      | Females    | Non-Hispanics | Hispanics   |
|------------------------|------------|------------|--------------|------------|
| Natural-log transformed fasting glucose | n = 501    | n = 554    | n = 620      | n = 435    |
| Main model             | 0.007 (–0.001, 0.015) | 0.009 (0.000, 0.017) | 0.006 (–0.001, 0.013) | 0.014 (0.002, 0.025) |
| Further adjusted model | 0.005 (–0.004, 0.014) | 0.008 (–0.001, 0.017) | 0.003 (–0.005, 0.010) | 0.016 (0.003, 0.030) |
| Natural-log transformed 2-hour glucose | n = 500    | n = 500    | n = 618      | n = 618    |
| Main model             | 0.022 (–0.004, 0.047) | 0.001 (–0.021, 0.023) | 0.008 (–0.012, 0.028) | 0.023 (–0.009, 0.054) |
| Further adjusted model | 0.018 (–0.012, 0.047) | 0.015 (–0.011, 0.040) | 0.010 (–0.012, 0.032) | 0.038 (0.001, 0.076)* |
| Natural-log transformed HOMA-IR | n = 501    | n = 553    | n = 620      | n = 434    |
| Main model             | 0.050 (0.019, 0.082)  | 0.036 (0.001, 0.071)  | 0.033 (0.005, 0.061)  | 0.076 (0.035, 0.118) |
| Further adjusted model | 0.038 (–0.001, 0.074) | 0.038 (–0.001, 0.076) | 0.025 (–0.009, 0.058) | 0.083 (0.037, 0.130)* |
| Natural-log transformed HOMA-β  | n = 501    | n = 553    | n = 620      | n = 434    |
| Main model             | 0.026 (–0.009, 0.061) | 0.005 (–0.030, 0.041) | 0.016 (–0.012, 0.043) | 0.021 (–0.028, 0.070) |
| Further adjusted model | 0.019 (–0.022, 0.060) | 0.013 (–0.026, 0.052) | 0.020 (–0.012, 0.053) | 0.021 (–0.033, 0.075) |

*Significant with \( p < 0.05 \).

*Main model adjusted for age (years; treated as time variable in Fine and Gray competing risks regression models), sex, ethnicity (Hispanic/non-Hispanic), education (<12/12/>12 years), smoking status (current/former/never), hypertension (dichotomous), body mass index (kg/m²), caloric intake (kcal/day), alcohol intake (g/week), and urinary creatinine (g/L).

Further adjusted model adjusted for all covariates in the Main model and also natural-log transformed arsenic, cadmium, and lead.

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) = [fasting insulin (µU/mL) × fasting glucose (mg/dL)]/405; Homeostatic Model Assessment of beta cell function (HOMA-β) = [20 × fasting insulin (µU/mL)]/fasting glucose (mg/dL) – 63.
insulin outcome data. No other characteristics significantly varied between individuals with and without outcome data. Additionally, we used urinary W levels measured at baseline, and we did not have data on time-varying changes in exposure. This may be a limitation since the majority (approximately 60% of daily intake) of ingested W is rapidly excreted through urine within a day.13 However, urinary W levels were highly correlated with W concentrations in drinking water for this study population (results not shown), and human intake of drinking water, although daily amounts may vary, is likely to remain relatively stable over longer periods due to the biologic requirement of water.6 Thus, we postulate that W levels excreted through urine may have also been relatively stable over time. Other biomarkers of arsenic and lead, such as hair and nail, are stronger biomarkers of long-term exposure.6,26 On the other hand, urinary cadmium is a strong biomarker of long-term cadmium exposure,64 and urinary measures of these other metals have been found suitable for biomonitoring.65,66

Other limitations include our assumption that the longitudinal exposure-response function was linear (as the BKMR analysis suggested that the cross-sectional exposure-response function was). Longitudinal trends were similar when quintiles of W as the exposure, which reduces concern of nonlinearity; however, as suggested by the BKMR results, there is still potential for a nonlinear association at higher lnW concentrations. We also did not account for potential confounding by certain other elements (e.g., nickel). We could not assess confounding by nickel, as this metal was not included in the metals panel. Since W has been suggested to increase negative health effects of nickel,10 there is still potential for unmeasured confounding. Finally, urinary W has been previously shown to be associated with chronic kidney disease in this population.14 Because we measured W in urine, it is possible that impaired kidney function could alter the urinary excretion of W,65 leading to misclassification of W measurements among those with kidney damage. However, we decided not to account for kidney function given the observed cyclical relationship between diabetes and kidney function.66,67

Although future studies are needed to examine how time-varying urinary W levels affect diabetes incidence in this population and in other populations, our longitudinal study suggests that exposure to W is associated with increased fasting glucose levels, HOMA-IR levels, and diabetes incidence. Given that W has industrial applications15 and exposure disparities persist,68 our results could inform future diabetes prevention efforts.

Conflicts of interest statement
The authors declare that they have no conflicts of interest with regard to the content of this report.

Acknowledgments
We would like to thank the participants and staff of the San Luis Valley Diabetes Study. All the intellectual property and data generated were administered according to policies from the University of Colorado and the NIH, including the NIH Data Sharing Policy and Implementation Guidance of March 5, 2003. The San Luis Valley Diabetes Study (SLVDS) summary data can be shared with the scientific community in accordance with the SLVDS data sharing plan (which includes Data Use Agreements and anonymizing of data to protect subject confidentiality). Analytic code is available upon reasonable request from the corresponding author.

References
1. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. US Dep Health Hum Serv. 2020:32.
2. Krishna S, Gillespie KN, McBride TM. Diabetes burden and access to preventive care in the rural United States. J Rural Health. 2010;26:3-11.
3. O’Connor A, Wellenius G. Rural-urban disparities in the prevalence of diabetes and coronary heart disease. Public Health. 2012;126:813–820.
4. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9:6–22.
5. Wang W, Xie Z, Lin Y, Zhang D. Association of inorganic arsenic exposure with type 2 diabetes mellitus: a meta-analysis. J Epidemiol Community Health. 2014;68:176–184.
6. Feng W, Cui X, Liu B, et al. Association of urinary metal profiles with altered glucose levels and diabetes risk: a population-based study in China. PLoS ONE. 2015;10:e0123742.
7. Khan F, Momtaz S, Niaz K, Hassan FI, Abdollahi M. Epigenetic mechanisms underlying the toxic effects associated with arsenic exposure and the development of diabetes. Food Chem Toxicol. 2017;107(Pt A):406–417.
8. Edwards J, Ackerman C. A review of diabetes mellitus and exposure to the environmental toxicant cadmium with an emphasis on likely mechanisms of action. Curr Diabetes Rev. 2016;12:252–258.
9. Khan AR, Arwan FR. Metals in the pathogenesis of type 2 diabetes. J Diabetes Metab Disord. 2014;13:16.
10. Bolt AM, Mann KK. Tungsten: an Emerging Toxin, Alone or in Combination. Curr Environ Heal Rep. 2016;3:405–415.
11. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Tungsten. US Public Health Serv. 2005:203.
12. Shah Idil A, Donaldson N. The use of tungsten as a chronically implanted material. J Neural Eng. 2018;15:020106.
13. Keith LS, Wohlers DW, Moffett DB, Rosemond ZA; Agency for Toxic Substances and Disease Registry. ATSDR evaluation of potential for human exposure to tungsten. Toxicol Ind Health. 2007;23:309–345.
14. Drinking Water Regulations. United States Environmental Protection Agency. 2015. Available at: https://www.epa.gov/dwreginfo/drinking-water-regulations. Accessed September 22, 2020.
15. US EPA. Emerging Contaminants and Federal Facility Contaminants of Concern. 2013. Available at: https://www.epa.gov/heliafدراس/emerging-contaminants-and-federal-facility-contaminants-concern. Accessed November 19, 2019.
16. Nominated Substances. National Toxicology Program. 2019. Available at: https://ntp.niehs.nih.gov/getinvolved/nominate/substances/index.html. Accessed November 19, 2019.
17. Shiue I, Hristova K. Higher urinary heavy metal, phthalate and arsenic concentrations accounted for 3-19% of the population attributable risk for high blood pressure: US NHANES, 2009-2012. Hypertens Res. 2014;37:1075–1081.
18. Tyrrell J, Galloway TS, Abo-Zaid G, Melzer D, Depledge MH, Osborne NJ. High urinary tungsten concentration is associated with stroke in the National Health and Nutrition Examination Survey 1999–2010. PLoS ONE. 2013;8:55779.
19. Fox, J., Macaluso F, Moore C, et al. Urine tungsten and chronic kidney disease in rural Colorado. Environ Res. 2021;195:110710.
20. Menke A, Guallar E, Cowie CC. Metals in urine and diabetes in U.S. adults. Diabetes. 2016;65:164–171.
21. Wang X, Karvonen-Gutierrez CA, Herman WH, Mukherjee B, Harlow BL. Metals in urine and incident diabetes in middle-aged women: study of Women’s Health Across the Nation (SWAN). BMJ Open Diabetes Res Care. 2020;8:e001233.
22. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37:278–316.
23. Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: issues on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409–420.
24. Gannon M, Kulkarni RN, Tse HM, Mauvais-Jarvis F. Sex differences underlying pancreatic islet biology and its dysfunction. Mol Metab. 2018;15:82–91.
25. Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-Cejudo JA. Hispanic health in the USA: a scoping review of the literature. Public Health Res. 2016;37:31.
26. James KA, Meliker JR, Marshall JA, Hokanson JE, Zerbe GO, Byers TE. Validation of estimates of past exposure to arsenic in drinking water using historical urinary arsenic concentrations. J Expo Sci Environ Epidemiol. 2013;23:430–454.
27. James KA, Byers T, Hokanson JE, Meliker JR, Zerbe GO, Marshall JA. Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in Colorado residents. Environ Health Perspect. 2015;123:128–134.
28. San Luis Valley Development Resources Group & Council of Governments. 2021 San Luis Valley Statistical Profile. 2021. SLVDRG.
